register

News & Trends - Pharmaceuticals

First-in-class therapy PBS listed for rare cancer of the eye

Health Industry Hub | February 2, 2024 |

Pharma News: Unlocking a treatment for uveal melanoma, a rare form of eye cancer, has long challenged scientists. Starting February 1st, patients with this aggressive cancer have access to Kimmtrak (tebentafusp), a first-in-class therapy Pharmaceutical Benefits Scheme (PBS) listed for unresectable or metastatic uveal melanoma.

Professor Anthony Joshua, Chair of the Australasian Ocular Melanoma Alliance (AOMA), emphasised the critical need for effective treatment, stating, “Advanced uveal melanoma is a particularly aggressive form of melanoma with a poor prognosis.” He went on to explain the mechanism of Kimmtrak, likening it to “velcro between the tumour and the immune system,” allowing immune cells to target and attack cancer cells.

The significance of this milestone was underscored by Professor Georgina Long AO, Co-Medical Director of Melanoma Institute Australia and 2024 Australian of the Year. She stated “This listing makes drug therapy for uveal melanoma accessible to Australian patients and provides us with more tools to tackle this rare form of melanoma.”

The therapy was PBS listed through a first Pharmaceutical Benefits Advisory Committee (PBAC) submission by Medison, the commercialisation partner for Immunocore in Australia. This is Medison’s first PBS launch locally.

Gil Gurfinkel, CEO of Medison Pharma, commented “We are pleased to see that our unified multi-regional commercial platform is enabling access to this innovative therapy for patients in Australia. Our efforts highlight our deep commitment to innovation, benefiting the communities we serve.”

The efficacy of Kimmtrak was established through a phase 3 trial involving 378 newly diagnosed patients. The trial compared Kimmtrak to three established treatments, including two immune checkpoint inhibitors and a chemotherapy drug. Of those in the control group, 82% were provided with Merck’s Keytruda. The results demonstrated a significant improvement in the median overall survival (OS), with Kimmtrak showing 21.7 months compared to 16 months for patients in the control group, along with a nearly 50% lower risk of death.

The most severe side effect of the therapy is cytokine release syndrome, necessitating a 16-hour monitoring period after the administration of the first three doses.

Ralph Torbay, Head of Commercial of Immunocore, stated “I am delighted that following the PBS listing, Australian patients can now access Kimmtrak demonstrating Immunocore’s commitment to bringing our medicines to patients worldwide.”

Adam Maguire, General Manager of Medison Australia, echoed this sentiment, saying, “Medison is committed to ensuring Australian patients have access to novel treatments as quickly as possible. The PBS listing of Kimmtrak is a significant step forward and we are proud to deliver access to this medicine for Australian patients.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.